Lv Xiaofeng, Wang Weijiao, Liu Xiaoyu, Liu Yuhuan, Guo Lili, Wang Changyu
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Genet. 2023 Jun 22;14:1213022. doi: 10.3389/fgene.2023.1213022. eCollection 2023.
Acyl-CoA thioesterase 13 (ACOT13) encodes a member of the thioesterase superfamily. It has not been reported in ovarian cancer. This research aimed at evaluating the expression and prognostic value of ACOT13 in ovarian serous cystadenocarcinoma (OSC). We extracted and analyzed TCGA, GEPIA, THPA, GTEx, miRWalk, and GDSC databases to investigate the potential carcinogenic mechanism of ACOT13 in OSC, including the correlation of ACOT13 with prognosis, immune checkpoint, tumor mutational burden (TMB), and 50% inhibition concentration (IC50) score. The incidence of endpoint events was compared with Kaplan-Meier survival analysis. Independent prognostic factors for OSC were evaluated with univariate and multivariate Cox regression analyses, and a nomogram was established. The expression of ACOT13 was increased in OSC and correlated with tumor stage, with higher expression in stages I and II than in stages III and IV. Besides, it was observed that low expression of ACOT13 is correlated with poor overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) in patients with OSC. There was a positive correlation between ACOT13 expression and immune checkpoint sialic acid-binding Ig-like lectin (SIGLEC) 15 and TMB. Patients with low ACOT13 expression had higher cisplatin IC50 scores. ACOT13 is an independent prognostic factor and a promising clinical target for OSC. In the future, the carcinogenic mechanism and clinical application value of ACOT13 in ovarian cancer need to be further studied.
酰基辅酶A硫酯酶13（ACOT13）编码硫酯酶超家族的一个成员。卵巢癌中尚未见相关报道。本研究旨在评估ACOT13在卵巢浆液性囊腺癌（OSC）中的表达及预后价值。我们提取并分析了TCGA、GEPIA、THPA、GTEx、miRWalk和GDSC数据库，以研究ACOT13在OSC中的潜在致癌机制，包括ACOT13与预后、免疫检查点、肿瘤突变负荷（TMB）和50%抑制浓度（IC50）评分的相关性。采用Kaplan-Meier生存分析比较终点事件的发生率。通过单因素和多因素Cox回归分析评估OSC的独立预后因素，并建立列线图。ACOT13在OSC中的表达增加，且与肿瘤分期相关，I期和II期的表达高于III期和IV期。此外，观察到ACOT13低表达与OSC患者的总生存期（OS）、无进展生存期（PFS）和疾病特异性生存期（DSS）较差相关。ACOT13表达与免疫检查点唾液酸结合免疫球蛋白样凝集素（SIGLEC）15和TMB呈正相关。ACOT13低表达的患者顺铂IC50评分较高。ACOT13是OSC的独立预后因素和有前景的临床靶点。未来，ACOT13在卵巢癌中的致癌机制和临床应用价值有待进一步研究。
